SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma

Abstract Background The combination of pemetrexed and cisplatin remains the reference first-line systemic therapy for malignant pleural mesothelioma (MPM). Its activity is moderate because of tumor aggressiveness, immune-suppressive environment and resistance to chemotherapy-induced immunogenic cell...

Full description

Bibliographic Details
Main Authors: Iris Chiara Salaroglio, Dimas Carolina Belisario, Paolo Bironzo, Preeta Ananthanarayanan, Luisa Ricci, Sabrina Digiovanni, Simona Fontana, Francesca Napoli, Alberto Sandri, Chiara Facolmatà, Roberta Libener, Valentina Comunanza, Federica Grosso, Elena Gazzano, Francesco Leo, Riccardo Taulli, Federico Bussolino, Luisella Righi, Mauro Giulio Papotti, Silvia Novello, Giorgio Vittorio Scagliotti, Chiara Riganti, Joanna Kopecka
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Malignant pleural mesothelioma
SKP/Cullin/F-box complex
endoplasmic reticulum stress
immunogenic cell death
Pevonedistat
Online Access:https://doi.org/10.1186/s13046-022-02284-7

Internet

https://doi.org/10.1186/s13046-022-02284-7

Similar Items